Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On June 30, 2015, Non-Executive Directors were allocated notional Ordinary Shares and American Depositary Shares (ADSs) for the service period of April 1, 2015, to June 30, 2015. The allocation prices were £13.45 per Ordinary Share and $42.20 per ADS. These allocations were notified to the Company and Directors on July 1, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs allocated to each Non-Executive Director listed in the filing.
- Confirm the allocation prices of £13.45 per Ordinary Share and $42.20 per ADS against market data for June 30, 2015.
- Review the Company's broader compensation policy for Non-Executive Directors to understand the context of these notional allocations.